149 related articles for article (PubMed ID: 36595482)
1. Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.
Wang K; Ye K; Zhang X; Wang T; Qi Z; Wang Y; Jiang S; Zhang K
J Med Chem; 2023 Jan; 66(1):1027-1047. PubMed ID: 36595482
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
Zhang K; Wang K; Zhang X; Qian Z; Zhang W; Zheng X; Wang J; Jiang Y; Zhang W; Lu Z; Hao H; Jiang S
J Med Chem; 2022 Jun; 65(11):7746-7769. PubMed ID: 35640078
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
[TBL] [Abstract][Full Text] [Related]
4. Switch of NAD Salvage to
Zhang J; Tao J; Ling Y; Li F; Zhu X; Xu L; Wang M; Zhang S; McCall CE; Liu TF
Front Immunol; 2019; 10():2358. PubMed ID: 31681271
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Dual Function Agents That Exhibit Anticancer Activity via Catastrophic Nicotinamide Adenine Dinucleotide Depletion.
Fu Y; Huang Y; Zhou C; Li X; Dong G; Huang M; Ding J; Sheng C
J Med Chem; 2023 Dec; 66(24):16694-16703. PubMed ID: 38060985
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
Yin C; Jia S; Yang X; Wu L
Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Biniecka P; Matsumoto S; Belotti A; Joussot J; Bai JF; Majjigapu SR; Thoueille P; Spaggiari D; Desfontaine V; Piacente F; Bruzzone S; Cea M; Decosterd LA; Vogel P; Nencioni A; Duchosal MA; Nahimana A
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838885
[TBL] [Abstract][Full Text] [Related]
8. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
[TBL] [Abstract][Full Text] [Related]
9. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
Nomura M; Ohuchi M; Sakamoto Y; Kudo K; Yaku K; Soga T; Sugiura Y; Morita M; Hayashi K; Miyahara S; Sato T; Yamashita Y; Ito S; Kikuchi N; Sato I; Saito R; Yaegashi N; Fukuhara T; Yamada H; Shima H; Nakayama KI; Hirao A; Kawasaki K; Arai Y; Akamatsu S; Tanuma SI; Sato T; Nakagawa T; Tanuma N
Nat Commun; 2023 Dec; 14(1):8095. PubMed ID: 38092728
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
11. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
13. Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase.
Song J; Zou G; Zhao Z; Zhu Y; Xue J; Ao L; Sun H; Hao H; Zhang B; Xu X
Chin J Nat Med; 2024 Jan; 22(1):75-88. PubMed ID: 38278561
[TBL] [Abstract][Full Text] [Related]
14. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
15. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
[TBL] [Abstract][Full Text] [Related]
18. Optimization of NAMPT activators to achieve in vivo neuroprotective efficacy.
Wang L; Liu M; Zu Y; Yao H; Wu C; Zhang R; Ma W; Lu H; Xi S; Liu Y; Hua L; Wang G; Tang Y
Eur J Med Chem; 2022 Jun; 236():114260. PubMed ID: 35385807
[TBL] [Abstract][Full Text] [Related]
19. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Bruzzone S; Fruscione F; Morando S; Ferrando T; Poggi A; Garuti A; D'Urso A; Selmo M; Benvenuto F; Cea M; Zoppoli G; Moran E; Soncini D; Ballestrero A; Sordat B; Patrone F; Mostoslavsky R; Uccelli A; Nencioni A
PLoS One; 2009 Nov; 4(11):e7897. PubMed ID: 19936064
[TBL] [Abstract][Full Text] [Related]
20. The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth.
Pant K; Richard S; Peixoto E; Yin J; Seelig DM; Carotenuto P; Salati M; Franco B; Roberts LR; Gradilone SA
Cells; 2023 Feb; 12(5):. PubMed ID: 36899911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
